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Autoimmune thyroid diseases (ATDs) represent the most frequent forms of the organ-speciﬁc autoimmune thyroid disorders
that result from interaction between genetic and environmental factors. Selenium has been shown to exert a beneﬁcial eﬀect on
the autoimmune thyroiditis. In spite of therapeutical eﬀect of selenium on autoimmunity, the mechanism of its action has not
been revealed. Objective. To determine whether selenium in vitro thyrocytes cultures are able to inﬂuence the HLA-DR molecule
expression of human thyrocytes and production of free oxygen radicals. Method. Thyrocytes were prepared from human thyroid
gland and cultured in vitro in the presence of interferon-γ and sodium selenite. The expression of HLA-DR molecules induced
by interferon-γ in the presence of sodium selenite of various concentration was measured by ﬂuorescence-activated cell sorter.
Results. Selenium has a dose-dependent inhibitory eﬀect on the expression of HLA-DR molecules of thyrocytes induced by
interferon-γ. This eﬀect of selenium was in the inverse correlation with antioxidative capacity. Conclusion.B e n e ﬁ c i a le ﬀect of
selenium on autoimmune mechanism is a complex mechanism in which the inhibitory eﬀect on HLA-DR molecule expression
and antioxidative capacity are involved into therapy of autoimmune thyroiditis.
1.Introduction
Recently published clinical studies on possible eﬀects of sele-
nium(Se)inautoimmunethyroiditisevokedexciting discus-
sion. The conﬂicting data were published on eﬀect of Se; the
one part of investigators provided evidences that Se intakes
may be beneﬁcial with respect to autoimmune diseases [1–
7],theotherswerenotabletoshowthesigniﬁcanteﬀectofSe
on autoimmune thyroiditis [8, 9]. Furthermore, the authors
whopublishedthebeneﬁcialeﬀectofSeonthelevelsofauto-
antibodies, advised to use Se therapy for patients with auto-
immune thyroiditis (AIT) [1, 4, 10]. Recently, we published
ourprospectiveplacebo-controlledprospectivestudyinclud-
ing 132 patients with autoimmune thyroiditis [4]. L-thyrox-
ine substitution therapy was made in both groups and the
level of TSH remained in the normal range. Se therapy was
continued by L-seleno-methionine (per os 2 × 100μg/day)
for one year. The level of Se in the untreated patients’ sera
was signiﬁcantly lower than in treated patients and controls,
and after three-month therapy with it, Se was normalized.
The titer of antithyroid antibodies (mostly the anti-TPO)
signiﬁcantly decreased at the end of study. An inverse
correlationwasfoundbetweenantioxidantcapacityandlevel
of anti-TPO antibodies. This observation suggests that Se
deﬁciency by itself might be responsible for the precipitation
of inﬂammatory process. Although the precise mechanisms
ofactionandthepossibletargetsofSehavenotbeenclariﬁed
yet, the beneﬁcial inﬂuence of Se can be explained by diﬀer-
ent points of views. Growing evidence supports that the sele-
nium-containing enzymes and their antioxidant capacity
somehow modify the autoimmune mechanism [11–15]. Pre-
viously, it was published that unlike in thyroids from
healthy individuals thyroid epithelial cells from patients with
AITD were able to express HLA class II antigen molecules
similar to normally expressed on antigen presenting cells
(APCs)suchasmacrophagesanddendriticcells[16–19].The
aberrant expression of HLA Class II molecules on thyroid
cells may initiate and perpetuate thyroid autoimmunity via
direct autoantigen presentation. We removed the repeated
references from the highlighted part. Please check similar2 Autoimmune Diseases
Table 1: Investigation of HLA-DR expression on thyrocytes induced by IFN-γ in the absence and presence of selenium. Figures in the table
represent mean percentage DR positive human thyroid cells ±SD. All experiments were made in triplicate. ns. = not signiﬁcant.
Culture of human thyrocytes Expression of HLA-DR on thyrocytes (%)
Culture media(n = 4) 3.7 ±2.4 P<0.001
IFN-γ (100 U/mL) 35.2 ±5.2 n.s
P<0.05
P<0.001 IFN-γ (100 U/mL) + sodium selenite (10nM/mL) (n = 3) 33.2 ±14.7
IFN-γ (100U/mL) + sodium selenite (50nM/mL) (n = 3) 26.4 ±12.7
IFN-γ (100 U/mL) + sodium selenite (100nM/mL) (n = 3) 11.5 ±5.2
cases throughout the paper. Previously we provided evidence
for the role of HLA-DR expression on thyrocytes induced by
interferon-γ (IFN-γ) and its modiﬁcation by methimazole
which has a signiﬁcant anti-oxidative capacity [20]. It was
assumed that the Se, like methimazole, can modify the
expression of HLA-DR molecules on thyrocytes culture in
the presence of Se; therefore, we made in vitro experiments
using human thyrocytes cultures to study this hypothesis.
2.MaterialsandMethods
We cultured human thyrocytes and analyzed HLA-DR
antigen expressions induced by IFN-γ in the various concen-
trations of sodium selenite (Sigma) in culture media by
previously published method [16]. Brieﬂy, thyroid epithelial
cells were separated from surgical specimens. 4–6 × 106 cells
were obtained from 10g of tissue with viability of >90%
which was determined by trypan blue exclusion. 2 × 105
cells were placed in each well of a 24-well Costar culture
plateandculturedinminimumessentialmediumcontaining
15% fetal calf serum (FCS) with 0.2% sodium bicarbonate
either alone (control wells) or in the presence of IFN-γ
(Hoﬀmann-La Roche), and to other wells 10.0, 50.0, and
100nmol/mL of sodium selenite (Sigma) were added. In
most of experiments, thyrocytes were cultured for 3 days and
then detached by 0.2% trypsin. HLA-DR expression was in-
vestigated initially (0 day) and on day 3 and 7 of culture.
Cells were recovered in Ca++ and Mg++ free EGTA solution
with rubber policeman. The detached cells were resuspended
in RPMI containing 10% FCS, 10mM HEPES (Sigma).
For indirect immunoﬂuorescence, cells were resuspended
in 200μL RPMI (Sigma) containing 10% FCS, in 10mM
HEPES and were incubated for 30min at 4◦Cw i t h5 . 0 μL
monoclonalanti-DRframeworkantibody(DAKO).Thecells
were washed twice and the pellet incubated for 30min at 4◦C
with 1:100 dilution of FITC-conjugated rabbit anti-mouse
immunoglobulin (Cooper Biomedical, Inc., Malvern, PA).
After two washes, the cells were analyzed in ﬂuorescence-
activated cell sorter (FACS III, Beckton-Dickinson Co.,
Sunnyvale,CA).Allexperimentsweremadeintriplicate.The
total antioxidant status (TAS) was determined by Randox kit
(Randox Laboratories Ltd, Crumlin, UK) [4, 12, 14].
2.1. Statistical Methods. The computerized program “Stat
View” (Version 4.5, SAS Institute Corp., North Carolina,
USA) was used for evaluating data. Descriptive statistics,
Pearson’s chi-square test, Fisher’s exact test, and ANOVA
analysis were performed. Values of P<0.05 were considered
as signiﬁcant.
3. Results
We found that IFN-γ (100U/mL) was able to induce a
signiﬁcant stimulation of expression of HLA-DR molecules
in thyrocytes (Table 1)( 3 5 .2 ± 15.2v e r s u s3 .7 ± 2.4, P<
0.001). The peak of HLA-DR expression was at day three and
then decreased abruptly. Therefore, we tested the expression
of HLA-DR positive cells induced by IFN-γ at day three in
absence and presence of Se of various concentrations. Se in
two diﬀerent concentrations (50nM/mL and 100nM/mL,
resp.) signiﬁcantly inhibited the expression of HLA-DR pos-
itive cells induced by IFN-γ (Table 1). If we added the Se to
thyrocytes cultures after or before exposition of IFN-γ, there
were not observed signiﬁcant changes in HLA-DR expres-
sion.Time-dependenteﬀectofsodiumselenite(100nM/mL)
on IFN-γ-induced HLA-DR expression(100U/mL) was on
Figure 1.ThenwestudiedthepossibleconnectionwithHLA-
DR expression on thyrocytes and antioxidant capacity of Se
and found an inverse correlation between antioxidant status
and expression of HLA-DR positive cells (r =− 0.72, P<
0.01) (Figure 2).
4. Discussion
ThetraceelementofSeplaysanimportantroleinthethyroid
gland under physiological conditions and in diseases as well.
Se supplementation decreased inﬂammatory activity in pa-
tients with autoimmune thyroiditis, and the reduction of ti-
tres of anti-TPO antibodies was correlated with serum levels
of Se [2, 4, 6, 7]. Convincing observation was published for
beneﬁcial eﬀect of Se in a patent with autoimmune thyroid-
itiswhenamarkeddecreaseinthyroid18FDGuptakeafterSe
supplementation was found [21]. In spite of great eﬀorts, the
precise mechanism of Se has not yet been clariﬁed. The role
of antioxidant property of Se was published to be involved
into beneﬁcial eﬀect in autoimmune thyroiditis [12–15].
Previously, we found that methimazole proved to have
antioxidant capacity decreased the expression of HLA-DR
moleculesonthesurfaceofthyrocytes[20].Ourexperiments
conﬁrmed that the Se has a signiﬁcant radical scavenging
eﬀect and the decrease the expression of HLA-DR molecu-
les induced by IFN-γ w a si na ni n v e r s ec o r r e l a t i o nw i t hAutoimmune Diseases 3
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Figure 1: Time-dependent eﬀect of sodium selenite (100nM/mL) on IFN-γ (100 U/mL) induced HLA-DR expression. (i) Dots: HLA-
DR expression without sodium selenite. (ii) Square: HLA-DR expression with sodium selenite (100nM/mL). (iii) Filled square: HLA-DR
expression with sodium selenite.
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Figure 2: Study of connection between antioxidant status and expression of HLA-DR positive cells. Bars show the ±SD, r =− 0.72.
antioxidative capacity of thyrocytes supernatant. The exoge-
nous factors including iodine and oxidative stress have been
publishedtobeprecipitatingfactorsingeneticallysusceptible
individuals [5, 14, 22–26]. The antigenicity of thyroid
autoantigens (thyroglobulin and TPO) is increased after
iodine exposition. The iodine is able to increase the amount
of free radicals which are produced in the process of physio-
logical hormonogenesis in the thyroid gland. In addition,
there are accumulating data for antiviral capacity of Se.
Both epidemiological and in vitro data demonstrated that
Se deﬁciency might be important in viral infections as well
[11]. Since the viruses have been published to induce IFN-
γ, consequently HLA-DR expression, therefore, it is hypo-
thesized that the trigger in autoimmune thyroiditis might be
a virus infection [27–29]. Nowadays, the suggestion of viral
origin of autoimmunity appears to be a speculation; howev-
er, the “selenium story” might open a new window not only
for better understanding of beneﬁcial eﬀect of Se in autoim-
mune thyroiditis but also in the research of origin of autoim-
munity [9, 11–13, 15, 22]. A new perspective has been op-
ened by the investigations of Se on the role of T regulatory
cells (Treg) with CD4CD25 FoxP3 markers [24, 25, 30,
31]. Accumulating data demonstrated that deﬁciency of
CD4+CD25+ T r e gc e l l sw a sc l o s e l yc o r r e l a t e dw i t hd e v e l o p -
ment of ATD [24, 25, 30, 31]. Recently, it was published
in animal experiments that the CD4CD25 FoxP3 T cells
displayedpreventiveeﬀectondevelopmentofATD[26].Sur-
prisingly, Se upregulated CD4+CD25+ regulatory T cells in
iodine-induced autoimmune thyroiditis model of NOD.H-
2h4 mice [24]. Our observation and experiments provide
evidence that Se has a complex eﬀect on immune system
including decreased expression on HLA-DR molecules and
by this way can prevent the induction and perpetuation of
autoimmune thyroid processes.
5. Conclusions
Se has a dose-dependent inhibitory eﬀect on the expression
of HLA-DR molecules of thyrocytes induced by interferon-
γ.T h i se ﬀect of selenium was in the inverse correlation with
anti-oxidative capacity. Inhibitory eﬀect of Se on HLA-DR
molecule expression and antioxidative capacity is involved
into therapy of autoimmune thyroiditis. Our in vitro study
provided evidence that the free radical scavenging eﬀect of
Se plays an important role in the therapy and the prevention
of autoimmunity.4 Autoimmune Diseases
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